Answers are grounded in this paper and cite their sources.
BALB/c mice are exceedingly susceptible to infection with Leishmania tropica such that failure to control a primary cutaneous lesion leads to metastasis and uniformly fatal visceralization. Substantial protective immunity can be induced by prophylactic immunization with gamma-irradiated promastigotes (150 K rad). Four weekly injections are more effective than a single immunization, and 2 × 107 is the optimal dosage (with activity extending down to 2 x 104). Intravenous immunization is superior to i.p. immunization in protecting against higher infecting doses, whereas both subcutaneous (s.c.) administration (even in conjunction with a range of adjuvants) and i.V. immunization subsequent to infection are totally ineffective. Protective immunity still persists after 150 days. Cross-protection is detectable against L. mexicana mexicana, L. mexicana amazonensis, and L. braziliensis panamensis. Within the challenge dose range of 2 × 103 to 2 x 106 L. tropica promastigotes, 100% mortality could be reduced to 0 to 33%, with 30 to 78% of infected mice developing minimal and healing primary lesions or no primary lesion. This outcome is comparable to that of prophylactic administration of 550 rad whereby BALB/c mice control the disease through developing cell-mediated immunity in the absence of suppressor T cell generation. In complete contrast, however, protective immunization itself induces no detectable DTH reactivity and no ‘memory’ recall on infection during which DTH develops normally and is not subject to suppression. Conversely, high titers of L. tropica-specific lgG1, lgG2a, lgG3, and IgM antibodies are induced by i.v. and i.p. but not s.c, immunization. The possibility of a causal role for this antibody response in conferring protection is discussed. The feasibility of immunization against the more severe forms of clinical leishmaniasis merits reconsideration in the face of these results, particularly if the prior generation of a cell-mediated response is not an a priori requirement.
No takes yet. Share an insight, caveat, or question.
Howard et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: